Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine dehydrogenase (NPSIXO) in patients with gout and/or hyperuricemia

Nucleosides, Nucleotides and Nucleic Acids

Volumn 23, Issue 8-9, 2004, Pages 1119-1122

  Komoriya, K ^a   Hoshide, S ^a   Takeda, K ^a   Kobayashi, H ^a   Kubo, J ^a   Tsuchimoto, M ^a   Nakachi, T ^b   Yamanaka, H ^c   Kamatani, N ^c  

^a TEIJIN LTD   (Japan)

^b TOCROM Clinic   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Febuxostat; Gout; Hyperuricemia; Pharmacodynamics; Pharmacokinetics; XOD XDH Inhibitor

Indexed keywords

ALLOPURINOL; FEBUXOSTAT; OXIPURINOL; PURINE ANTAGONIST; XANTHINE DEHYDROGENASE; XANTHINE OXIDASE INHIBITOR;

ADULT; AREA UNDER THE CURVE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; FEMALE; GOUT; HUMAN; HYPERURICEMIA; MALE; PHASE 2 CLINICAL TRIAL; URINARY EXCRETION;

AREA UNDER CURVE; ENZYME INHIBITORS; GOUT; HUMANS; HYPERURICEMIA; MALE; OXYGEN; THIAZOLES; TIME FACTORS; XANTHINE DEHYDROGENASE; XANTHINE OXIDASE;

EID: 10344222996     PISSN: 15257770     EISSN: None     Source Type: Journal    
DOI: 10.1081/NCN-200027381     Document Type: Conference Paper

References (5)

1. Ishiwata, Y.; Kubo, J.; Komoriya, K.; Yamanaka, H.; Kamatani, N. TMX-67, a novel xanthine oxidase/xanthine dehydrogenase (XOD) inhibitor, shows strong uric acid lowering action in patients with hyperuricemia and gout. Arthritis Rheum. 2001, 44 (Suppl), S129.
2. Joseph-Ridge, N. Phase II, dose-response, safety and efficacy clinical trial of a new oral xanthine oxidase inhibitor TMX-67 (febuxostat) in subjects with gout. Arthritis Rheum. 2002, 46 (Suppl), S142.
3. Ohnishi, A.; Kubo, J.; Tanaka, D.; Yonezawa, H.; Horiuchi, H.; Hoshide, S.; Sakuma, Y.; Tsuchimoto, M.; Komoriya, K.; Yamanaka, H.; Kamatani, N. Pharmacokinetics and hypouricemic effect of a novel xanthine oxidase/dehydrogenase inhibitor following the single and repeated administrations in man. Clin. Pharmacol. Ther. in preparation.
4. Osada, Y.; Tsuchimoto, M.; Fukushima, H.; Takahashi, K.; Kondo, S.; Hasegawa, M.; Komoriya, K. Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents. Eur. J. Pharmacol. 1993, 241, 183-188.
5. Komoriya, K.; Osada, Y.; Hasegawa, M.; Horiuchi, H.; Kondo, S.; Couch, R.C.; Griffin, T.B. Hypouricemic effect of allopurinol and the novel xanthine oxidase inhibitor TEI-6720 in chimpanzees. Eur. J. Pharmacol. 1993, 250, 455-460.